Product Overview
Ligandrol, usually written by its research code LGD-4033, is an oral non-steroidal selective androgen receptor modulator. The molecule was designed as a tissue-selective alternative to a classical androgen: it binds the androgen receptor with the intention of producing anabolic activity in muscle and bone while leaving prostate and skin activity behind. Dragon Pharma supplies the material as a tablet, 15 mg of active substance per tablet, 100 tablets to a pack, and the product sits in the catalogue SARM group next to MK 2866 and the GW501516 Cardarine entry.
The human record is thin and it sits a long way below the amounts that circulate outside laboratories. The trial most vendor pages quote gave 76 healthy men 1 mg a day for three weeks and reported an average gain of 1.2 kg of lean body mass without a prostate signal. Repeat-dose work covers 0.1 to 2 mg per day across three to twelve weeks. A 15 mg tablet therefore carries several times to more than a hundred times the studied amount, and no human study has charted a course at that level. Ligandrol was never approved as a medicine anywhere, it is named on the WADA prohibited list, and the FDA has warned about SARM products as a group, listing heart attack and stroke among the risks a user should consider.
Because the parent compound clears in under two days, a single daily dose is enough to keep levels reasonably steady. That easy part of the picture is not the whole picture: even modest doses suppress the body's own testosterone and pull HDL cholesterol down, which is the reason a blood panel belongs in week one of a run rather than at the point where something feels wrong.
Dosage Protocol
No approved dose exists. The rows below keep the clinical range and the non-medical range apart on purpose, because the distance between them is the single most important fact about this tablet.
| Beginner | 5 mg a day for 8 weeks, a level that already exceeds the highest repeat-dose used in a published trial |
| Intermediate | 5-10 mg a day for 8-12 weeks, with testosterone, HDL and ALT/AST taken at baseline and again near week 4 |
| Advanced | 10-15 mg a day for 8-12 weeks, the ceiling of the non-medical range and a zone no human study has covered |
| Female | No confirmed female schedule appears in the sources behind this card; masculinising effects in women are almost unstudied, so no protocol can be quoted honestly |
| Administration | Oral, once a day; the pack is one 15 mg tablet and does not divide into a clean 5 mg line, so the marketed unit sits at the top of the range |
| Study reference | 0.1-2 mg a day over 3-12 weeks in the literature, plus 1 mg a day for 3 weeks in the 76-man lean mass trial |
Suggested Protocols
Nothing in the published record qualifies as a validated combination, so the cards below describe how this material is grouped in practice, using items from the same brand section. Treat them as catalogue groupings, not as clinical protocols.
What to Expect
- First signals. Most accounts place the change in training quality in the opening two to three weeks, which matches the onset seen in the clinical work.
- Lean mass. The published benchmark is 1.2 kg of lean body mass at 1 mg a day over three weeks in 76 men, which is a useful anchor rather than a promise for a longer run at a higher dose.
- Strength. Gains in working weights track the lean mass change and stay tied to training and protein intake.
- Own testosterone. Total and free testosterone, FSH and SHBG all moved down in the studies, so a low-testosterone tail after the run is expected rather than unusual.
- Cholesterol. HDL fell in the same trials while LDL stayed level, which is the pattern to watch on a lipid panel.
- Liver values. Enzyme rises have been recorded in the literature, so ALT and AST belong in the monitoring set.
- Ceiling. Market doses run well above any studied amount, and the long-term consequences of that gap are simply unknown.
Side Effects and Management
Almost every item below is a class behaviour of a suppressive oral SARM, and almost all of them are visible on ordinary bloodwork before they are visible in a mirror.
Post-Cycle Therapy
Recovery here is a waiting game with a defined start line, because the drug leaves quickly but the axis does not reset on its own timetable.
